Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise

Abstract

Based on this modeling exercise, it could be expected that LAR may be a cost-effective treatment with limited budget impact in Portugal. However, further studies are required to test the generalizability of the results of the present modeling study to the larger population of Portugal.